Identification of N-terminally truncated pyroglutamate amyloid-β in cholesterol-enriched diet-fed rabbit and AD brain

Journal of Alzheimer's Disease

Volumn 39, Issue 2, 2014, Pages 441-455

  Perez Garmendia, Roxanna ^a   Hernandez Zimbron, Luis Fernando ^a   Morales, Miguel Angel ^a   Luna Muñoz, José ^b   Mena, Raul ^b   Nava Catorce, Miriam ^a   Acero, Gonzalo ^a   Vasilevko, Vitaly ^c   Viramontes Pintos, Amparo ^b   Cribbs, David H ^c,d   Gevorkian, Goar ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid ; animal model; cholesterol fed rabbit; pyroglutamate modified amyloid

Indexed keywords

AMYLOID BETA PROTEIN; PYROGLUTAMIC ACID;

AGING; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CHOLESTEROL DIET; CONTROLLED STUDY; DOT HYBRIDIZATION; EXPERIMENTAL RABBIT; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ALZHEIMER'S DISEASE; AMYLOID-Β; ANIMAL MODEL; CHOLESTEROL-FED RABBIT; PYROGLUTAMATE-MODIFIED AMYLOID;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ASTROCYTES; BRAIN; CEREBRAL CORTEX; CHOLESTEROL, DIETARY; EXTRACELLULAR SPACE; HIPPOCAMPUS; HUMANS; INTRACELLULAR SPACE; MALE; MICE; MICE, TRANSGENIC; NEURONS; PEPTIDE FRAGMENTS; RABBITS;

EID: 84893927883     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130590     Document Type: Article

References (67)

1. Masters CL, Simms G,Weinmann NA,Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.
2. WalshDM,Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193.
3. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
4. LaFerla F, Green KN, Oddo S (2007) Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
5. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010) Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 119, 523-541.
6. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377, 1019-1031.
7. Ferreira ST, Klein WL (2011) The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96, 529-543.
8. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267, 17082-17086.
9. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schiossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
10. Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 14, 457-466.
11. Tekirian TL, Markesbery WR, Russel MJ,Wekstein DR, Patel E, Geddes JW (1998) N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol 57, 76-94.
12. Guntert A, Dobeli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461-475.
13. Gunn AP, Masters CL, Cherny RA (2010) Pyroglutamate-Aβ: Role in the natural history of Alzheimer's disease. Int J Biochem Cell Biol 42, 1915-1918.
14. Harigaya Y, Saido TC, Eckman C, Prada C-M, Shoji M, Younkin SG (2000) Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276, 422-427.
15. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, MilthaupG(2010) Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 117, 85-96.
16. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA (2010) Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease. A novel tool for therapy and diagnosis. J Biol Chem 285, 41517-41524.
17. Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270, 23895-23898.
18. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G (2002) Pyroglutamate-modified amyloid betapeptides-AβN3(pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 82, 1480-1489.
19. Schilling S, LauberT, Schaupp M, Manhart S, Scheel E,Bohm G, Demuth H-U (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45, 12393-12399.
20. Youssef I, Florent-Bechard S, Malaplate-Armand C, Koziel V, Bihain B, Olivier J-L, Leininger-Muller B, Kriem B, Oster T, Pillot T (2007) N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 29, 1319-1333.
21. D'Arrigo C, Tabaton M, Perico A (2009) N-terminal truncated pyroglutamyl β amyloid peptideAβpy3-42 shows faster aggregation kinetics than the full-length Aβ1-42. Biopolymers 91, 861-873.
22. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature 485, 651-655.
23. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, Terenius L (1994) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91, 8378-8382.
24. Huse JT, Liu K, Pijak DS, Carlin D, Lee VM-Y, Doms RW (2002) β-Secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J Biol Chem 277, 16278-16284.
25. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David J-P, Vanmechelen E, Sergheraert C, Delacourte A (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 85, 1581-1591.
26. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E (2005) Amino-truncated β-amyloid 42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 51, 1650-1660.
27. Casas C, Sergeant N, Itier J-M, Blanchard V, Wirths O, van der Kolk N, Vingtdeux, V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides. J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1/2 neuronal loss with intraneuronal and nterminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165, 1289-1300.
28. Bayer TA, Breyahn H, Duan K, Rettig J, Wirths O (2008) Intraneuronal β-amyloid is a major risk factor-novel evidence from the APP/PS1KI mouse model. Neurodegener Dis 5, 140-142.
29. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118, 487-496.
30. Alexandru A, Jagla W, Graubner S, Becker A, Bauscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Ronicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rubsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth H-U, von Horsten S (2011) Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβis induced by pyroglutamate- Aβformation. J Neurosci 31, 12780-12801.
31. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H-U, Blennow K, Wirths O, Bayer TA (2012) Pyroglutamate Abeta aggravates behavioral deficits in 5XFAD mice. J Biol Chem 287, 8154-8162.
32. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Landler C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nat Med 14, 1106-1111.
33. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H-U, Lemere CA (2012) Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: A pilot study. Neurodegener Dis 10, 265-270.
34. DeMattos R, Lu J, Tang Y, RackeMM, DeLong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML (2012) A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 76, 908-920.
35. Jawhar S,Wirths O, Bayer TA (2011) Pyroglutamate amyloid β(Aβ):Ahatchet man in Alzheimer disease. J Biol Chem 286, 38825-38832.
36. Kawarabashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid(beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381.
37. Kalback W, Watson MD, Kokjohn TA, Kuo Y-M, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, RoherAE(2002)APPtransgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41, 922-928.
38. Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, George-Hyslop PS, Ikezu T, Schilling S, Demuth HU, Lemere CA (2013) Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol 183, 369-381.
39. Jawhar S, Wirths O, Schilling S, Graubner S, Demuth H-U, Bayer TA (2011) Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamateAβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem 286, 4454-4460.
40. Breyhan H, Wirths O, Duan K, Marcello A, Rettig J, Bayer TA (2009) APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol 117, 677-685.
41. Sparks DL, Scheff SW, Hunsaker JC3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
42. Zatta P, Zambenedetti P, Stella MP, Licastro F (2002) Astrocytosis, microgliosis, metallothionein-I-II and amyloid expression in high cholesterol-fed rabbits. J Alzheimers Dis 4, 1-9.
43. Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 100, 11065-11069.
44. Woodruff-Pak DS, Agelan A, Del Valle L (2007) A rabbit model of Alzheimer's disease: Valid at neuropathological, cognitive, and therapeutic levels. J Alzheimers Dis 11, 371-383.
45. Ghribi O (2008) Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis 15, 673-684.
46. Prasanthi RPJ, Schommer E, Thomasson S, Thompson A, Feist G, GhribiO(2008) Regulation of β-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech Ageing Dev 129, 649-655.
47. Sparks DL (2008) The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: The old, the new and the pilot. J Alzheimer Dis 15, 641-656.
48. Sparks DL, Ziolkowski C, Lawmaster T, Martin T (2011) Influence of water quality on cholesterol-induced tau pathology: Preliminary data. Int J Alzheimers Dis 2011, 987023.
49. Deci S, Lemieux SK, Smith-Bell CA, Sparks DL, Schreurs BG (2012) Cholesterol increases ventricular volume in a rabbit model of Alzheimer's disease. J Alzheimers Dis 29, 283-292.
50. Prasanthi JR, Schrag M, Dasari B, Marwarha G, Kirsch WM, GhribiO(2012) Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis 30, 167-182.
51. Perez-Garmendia R, Ibarra-Bracamontes V, Vasilevko V, Luna-Munoz J, Mena R, Govezensky T, Acero G, Manoutcharian K, Cribbs DH, Gevorkian G (2010) Anti-11 [E]-pyroglutamate-modified amyloid β antibodies crossreact with other pathological Aβ species: Relevance for immunotherapy. J Neuroimmunol 229, 248-255.
52. Acero G, Manoutcharian K, Vasilevko V, Munguia ME, Govezensky T, Coronas G, Luz-Madrigal A, Cribbs DH, Gevorkian G (2009) Immunodominant epitope and properties of pyroglutamate-modified Aβ-specific antibodies produced in rabbits. J Neuroimmunol 213, 39-46.
53. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari R, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron 39, 409-421.
54. Hernandez-Zimbron LF, Luna-Munoz J, Mena R, Vazquez-Ramirez R, Kubli-Garfias C, Manoutcharian K, Gevorkian G (2012) Amyloid-β peptide binds to cytochrome c oxidase subunit 1. PLOS One 7, e42344.
55. Munch G, Robinson SR (2002) Potential neurotoxic inflammatory responses to Aβ vaccination in humans. J Neural Transm 109, 1081-1087.
56. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR, (2004) Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in non-human primate, the Caribbean vervet. Am J Pathol 165, 283-297.
57. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, Milton S, Barrett EG, Cotman CW, Cribbs DH, Head E (2010) Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis 39, 301-310.
58. Martin SB, Dowling ALS, Head E (2011) Therapeutic interventions targeting beta amyloid pathogenesis in an aging dog model. Curr Neuropharmacol 9, 651-661.
59. Hartig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J (2010) Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. J Chem Neuroanat 40, 82-92.
60. Chambers JK, Mutsuga M, Uchida K, Nakayama H (2011) Characterization of AbpN3 deposition in the brains of dogs of various ages and other animal species. Amyloid 18, 63-71.
61. Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG (2011) Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis 24, 315-325.
62. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22, 7873-7878.
63. Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG (2012) Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci 32, 2696-2702.
64. Miles LA, Crespi GAN, Doughty L, Parker MW (2013) Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep 18, 1302.
65. Savory J, Herman MM, Ghribi O (2006) Mechanisms of aluminum-induced neurodegeneration in animals: Implications for Alzheimer's disease. J Alzheimers Dis 10, 135-144.
66. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY (2003) Astrocytes accumulate Abeta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971, 197-209.
67. De Kimpe L, van Haastert ES, Kaminari A,Zwart R, Rutjes H, Hoozemans JJM, Scheper W (2012) Intracellular accumulation of aggregated pyroglutamate amyloid beta: Convergence of aging and Aβ pathology at the lysosome. Age (Dordr) 35, 673-687.